Ignite Creation Date:
2024-05-06 @ 7:27 PM
Last Modification Date:
2024-10-26 @ 3:07 PM
Study NCT ID:
NCT06015880
Status:
RECRUITING
Last Update Posted:
2024-07-03
First Post:
2023-08-26
Brief Title:
Testing the Combination of Anti-cancer Drugs Mosunetuzumab Polatuzumab Vedotin and Lenalidomide for the Treatment of RelapsedRefractory Diffuse Large B-Cell Lymphoma
Sponsor:
National Cancer Institute NCI
Organization:
National Cancer Institute NCI
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-05-20
Start Date Type:
ACTUAL
Primary Completion Date:
2026-06-29
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-06-29
Completion Date Type:
ESTIMATED
First Submit Date:
2023-08-26
First Submit QC Date:
August 26 2023
Study First Post Date:
2023-08-29
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-08-22
Last Update Post Date:
2024-07-03
Last Update Post Date Type:
ACTUAL